منابع پایان نامه درمورد and، of، cervical، the

Samsami Dehaghani A, Tabei SZ, Kumar VP, and Ghaderi A. High Risk I-IPV Types in Southern Iranian Patients with Cervical Cancer. Pathol Oncol Res 2003; 9(2): 121-125.
128. Maleknejad P, Rakhshan tvl, Kazemi B, Farokh F, Shahsavan S. Detection of human papillomavirus type 16 and 18 in pathologic samples from patients with cervical cancer by PCr and RFLP methods. Daru 2006; 14(2): 78-81.
129. Mokhtari-Azad T, IvIoradi A, Khodayari-Nemin A, Keikhaee MR, Sargolzaei S, and Shahrokhi M. Detection of human papillomavirus DNA in lntraosseus Ameloblastoma. Int J Virol 2006; 2(1): 1-6.
130. Nadji SA, Molchtari-Azad T, Mahmoodi M, Yahyapour Y, Naghshvar F, Torabizadeh J, Ziaee AA, Nategh R. Relationship between lung cancer and human papillomavirus in north of Iran, Mazandaran province. Cancer Lett 2007; 248(1): 41-46.
131. Stanczuk GA, Kay P, Allan B, Chirara M, Tswana SA, Bergstrom S, Sibanda EN, and Williamson AL. Detection of Human papillomavirus in urine and cervical swabs from patients with invasive cervical cancer. J Med Virol 2003; 71: 110-114.
132. Chen BY, and Janes HW. PCR cloning protocols, Humana Press. 2Ild edition, 2002.
133. Devaraj K, Gillison ML, and Wu TC. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med 2003; 14(5): 345-362.
134.Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, and Wu TC. Cancer Immunotherapy Using a DNA Vaccine Encoding the Translocation Domain of a Bacterial Toxin Linked to a Tumor Antigen. Cancer Res 2001; 61: 3698-3703.
135. Hohn H, Pilch H, Gunzel S, Neukirch C, Hilmes C, Kaufmann A, Seliger B, and Maeurer MJ. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J lmmunol 1999; 163: 5715-5722.
136. Kast WM, Brandt RMP, Sidney J, Drijfhout JW, Kubo RT, Grey HM, Melief CJM, and Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994; 152: 3904-3912.
137. Luxton JC, Nath R, Derias N, Herbert A, and Shepherd PS. Human papillomavirus type 16- specific T cell responses and association with recurrence of cervical disease following treatment. J Gen Virol 2003; 84: 1063-1070.
138. Lin CT, Hung CF, Juang J, He L, Lin KY, Kim TW, and Wu TC. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and anti tumor effects of HPV16 E7-expressing sindbis virus replicon particles. Mol Ther 2003; 8(4): 559-566.
139. Santin AD, Hermonat PL, Ravaggi A, Chiriva-Internati M, Hiserodt JC, Batchu RB, Pecorelli S, and Parham GP. The effects of irradiation on the expression of a tumor rejection antigen (heat shock protein gp96) in human cervical cancer. Int J Radiat Biol 1998; 73(6): 699-704.
140. Haupt K, Roggendorf M, and Mann K. potential of DNA vaccination against tumor-associated antigens for anti tumor therapy. Exp Bio Med 2002; 227(4): 227-237.
141. Barry MA, and Johnston SA. Biological future of genetic immunization. Vaccine 1997; 15(8): 788-791.
142. Schedlocic DJ, and Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukocyte Biol 2000; 68: 793-806.
143. NIAID Task Force on Immunology. 1998. Report of the NIAID Task Force on Immunology. U.S. Department of Health Human Services, Bethesda, MD.
144. Tindle, R. 1996. Human papillomavirus vaccines for cervical cancer. Current Opinion in Immunology 8(5):643-650. Available online at www.biomednet.com/library/fulltext/JIMM.im8502.
145. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. Journal of Virology, 1993, 67(1):315–322.
146. Robinson, HL et al. 1997. The Scientific Future of DNA for Immunization. American Society for Microbiology, Washington, D.C. Available online at www.asmusa.org/acarc/aca1.htm.
147. Doepel, LK. 1998. First human trial shows that an edible vaccine is feasible. NIAID News, April 27, 1998. NAIAD Office of Communications and Public Liaison,Bethesda,MD.Available online at www.niaid.nih.gov/newsroom/ediblevacc.htm.
148. Lowy, DR and Schiller, JT. 1998. Papillomaviruses: prophylactic vaccine prospects. Biochimica et Biophysica Acta 1423:M1-M8.
149. Duggan-Keen, MF et al. 1998. Papillomavirus vaccines. Frontiers in Bioscience 3:1192-1208. Available online at www.bioscience.org/1998/v3/ d/duggan/ d1208.htm.
150. Van Driel, WJ et al. 1999. Immunotherapeutic strategies for cervical squamous carcinoma. Current Therapeutic Issues in Gynecologic Cancer 13(1):259-271.
151. Lowy, DR and Schiller, JT. 1998. Papillomaviruses and cervical cancer: pathogenesis and vaccine development. Journal of the National Cancer Institute Monographs 23:27-30.
152. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID). 1998. Understanding Vaccines. NIH Publication No. 98-4219. US Department of Health Human Services, Bethesda, MD.
153. Zhou J et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185(1):251–257.
154. Monie A, Hung CF, Roden R, Wu TC. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics. 2008 Mar;2(1):97-105.
155. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011 Jan 15;186(2):1022-31.
156. Lexchin J, Arya N, Singh S. Gardasil(R) – The New HPV Vaccine: The Right Product, the Right Time? A Commentary. Healthc Policy. 2010 May;5(4):26-36.
157. Merck USA. GARDASIL®Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant: GARDASIL® full prescribing information,2007.(http://www.merck.com/product/usa/pi_circulars/g/ gardasil_pi.pdf, accessed 25 September 2008).
158. GlaxoSmithKline Australia. Cervarix® product information: human papillomavirus vaccine type 16 and 18 (Recombinant

پاسخی بگذارید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *